Posts Tagged ‘treatment’
NEW: Pfizer antiviral pill, Paxlovid, showing 88% reduced risk of hospitalization/death if taken within 5 days of first symptom
Pfizer today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). These results were consistent with the interim analysis announced in November 2021, showing…
Read MoreCOVID-19. There’s a pill for that? Merck revs up production while waiting approval
Photo: Merck A new drug, Molnupiravir, an investigational oral antiviral medicine, was shown to significantly reduce the risk of hospitalization or death for at risk, non-hospitalized adult patients with mild to moderate COVID-19. Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral…
Read More